Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gefitinib + tamoxifen
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gefitinib + tamoxifen is a combination therapy that targets both the epidermal growth factor receptor (EGFR) and estrogen receptor (ER) pathways simultaneously. This combination approach aims to overcome resistance mechanisms in breast cancer treatment. Gefitinib inhibits EGFR tyrosine kinase activity, while tamoxifen acts as an estrogen receptor antagonist. The combination has been studied particularly for its potential in treating triple-negative breast cancer and hormone receptor-positive breast cancer that has developed resistance to single-agent therapy. Some research has explored hybrid ligands that connect tamoxifen or endoxifen with gefitinib via a covalent linkage, which may offer advantages of pharmacokinetic simplicity and fewer drug-drug interactions compared to administering the drugs separately.
- Other names
- Gefitinib-Tamoxifen Hybrid Ligands
02
Targets
ESR1 (ERα)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on gefitinib + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gefitinib + tamoxifen.